查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1404948

肿瘤临床试验市场规模、份额和趋势分析报告：按阶段类型、研究设计、地区和细分市场进行预测（2023-2030）

Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase Type (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Study, Observational Study, Expanded Access Study), By Region, & Segment Forecasts, 2023-2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

肿瘤临床试验市场成长与趋势：

预计2030年，全球肿瘤临床试验市场规模将达到194.9亿美元，2023年至2030年复合年增长率为5.2%。

肺癌是全球癌症相关死亡的主要原因，美国每年估计有 180 万人被诊断出肺癌，大约有 60,000 例新诊断的肾细胞癌病例，使癌症患者的生活变得更加困难。预计人数增加。此外，它还反映了癌症盛行率的不断上升以及对有效癌症治疗的需求不断增加。

联邦政府在资助和组织肿瘤学临床研究方面发挥重要作用。 NCI 资助了美国近一半的肿瘤临床试验，并且 II 期试验的数量不断增加，导致市场成长。此外，根据药品保健产品监管局 (MHRA) 的数据，2018 年至 2022 年间，II 期和 III 期申请增加了 5.5%。 IQVIA 于 2019 年 9 月宣布与癌症研究人员建立合作关係，以加强真实世界资料的使用并扩大肿瘤学临床研究。

肿瘤临床试验市场报告亮点

  • 按阶段类型划分，III 期细分市场预计在预测期内将以 5.6% 的复合年增长率成长最快。第三期的份额很高，因为虽然它是最昂贵的，但涉及的科目较多。第三阶段涉及註册和上市后承诺的长期安全研究。
  • 从试验设计来看，介入试验部分在 2022 年占据最大的收益占有率，达到 87.5%。肿瘤临床试验领域的介入试验设计主要是由这些疾病的独特挑战所驱动的。
  • 由于该地区完善的药品和药物检测法规，北美在 2022 年以 41.8% 的销售份额占据市场主导地位。由于中国和印度等新兴经济体开拓的商机，预计亚太地区在预测期内将以 7.1% 的复合年增长率成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章肿瘤临床试验市场变数与趋势

  • 市场动态
    • 市场驱动因素影响分析
    • 市场抑制因素影响分析
    • 市场机会影响分析
    • 市场问题的影响分析
  • 产业分析工具
    • 波特的分析
    • 宏观经济分析

第四章肿瘤临床试验市场：阶段类型分析

  • 相型波动分析及市场占有率（2022/2030）
  • 按阶段
  • 阶段型市场规模、预测与趋势分析（2018-2030）
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段

第五章肿瘤临床试验市场：研究设计分析

  • 研究设计变异分析与市场占有率（2022/2030）
  • 透过研究设计
  • 研究设计市场规模、预测与趋势分析（2018-2030）
    • 侵扰性的
    • 观察性的
    • 延长访问试用期

第六章肿瘤临床试验市场：区域估计与趋势分析

  • 肿瘤临床试验市场：区域展望
  • 北美洲
    • 北美肿瘤临床试验市场估计与预测（2018-2030）
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 丹麦
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争分析

  • 企业竞争形势
  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • AstraZeneca
    • Merck & Co., Inc
    • IQVIA Inc
    • Gilead Sciences, Inc
    • F. Hoffmann-La Roche Ltd
    • PAREXEL International Corporation
    • PRA Health Sciences
    • Medpace
    • Pivotal

第8章分析师的观点

Product Code: GVR-4-68039-139-7

Oncology Clinical Trials Market Growth & Trends:

The global oncology clinical trials market size is expected to reach USD 19.49 billion by 2030, registering a CAGR of 5.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. The number of people living with cancer is predicted to rise as lung cancer is the largest cause of cancer-related deaths worldwide, with an estimated 1.8 million people diagnosed and around 60,000 new cases of renal cell carcinoma diagnosed in the U.S. each year. Furthermore, it reflects an increasing prevalence of cancer and an increasing demand for efficient cancer treatment.

The federal government plays a huge role in funding and organizing clinical research in oncology. NCI funds nearly half of all cancer trials in the U.S., and there's a growing number of studies in phase II, leading to market growth. Moreover, according to the Medicines Healthcare Products Regulatory Agency (MHRA), between 2018 and 2022, the application for phase II and phase III trials increased by 5.5%. IQVIA announced a relationship with Cancer Researchers in September 2019 to enhance the use of real-world data and expand clinical research in oncology.

Oncology Clinical Trials Market Report Highlights:

  • Based on phase type, the phase III segment is expected to grow at the fastest CAGR of 5.6% during the forecast period. Phase III segment includes the high share of phase III trials, which is attributed to the fact that phase III trials are the most expensive but involve many subjects. Long-term safety studies are conducted for registration and post-marketing commitments in phase III trials
  • Based on study design, the interventional studies segment accounted for the largest revenue share of 87.5% in 2022. The driving factors for interventional study design in the oncology clinical trials sector primarily revolve around these conditions' unique challenges
  • North America dominated the market with a revenue share of 41.8 % in 2022 owing to the well-established pharmaceutical and drug trials regulations in the region. Asia Pacific is anticipated to grow at the fastest CAGR of 7.1% over the forecast period due to the presence of untapped opportunities in the emerging economies of China and India

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis
      • 1.6.1.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3

Chapter 2 Executive Summary

  • 2.1 Market Outlook
    • 2.1.1 Regional Insights
    • 2.1.2 Competitive Landscape
  • 2.2 Market Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Segment Snapshot
  • 2.5 Competitive Landscape

Chapter 3 Oncology Clinical Trials Market Variables and Trends

  • 3.1 Market Dynamics
    • 3.1.1 Market driver impact analysis
      • 3.1.1.1 Increasing prevalence of Cancer
      • 3.1.1.2 Rise in the number of CROs for conducting research activities
    • 3.1.2 Market restraint impact analysis
      • 3.1.2.1 High cost associated with oncological clinical trial
    • 3.1.3 Market Opportunities impact analysis
      • 3.1.3.1 Technological Advancements
    • 3.1.4 Market challenges impact analysis
      • 3.1.4.1 Strict regulations for patient enrollment in clinical trials
  • 3.2 Industry Analysis Tools
    • 3.2.1 Porter's analysis
    • 3.2.2 Macroeconomic analysis

Chapter 4 Oncology Clinical Trials Market: Phase Type Analysis

  • 4.1 Type Movement Analysis & Market Share, 2022 & 2030
  • 4.2 Oncology Clinical Trials Market Estimates & Forecast, By Phase (USD Million)
  • 4.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the Type
    • 4.3.1 Phase I
      • 4.3.1.1 Phase I market, 2018 - 2030 (USD Million)
    • 4.3.2 Phase II
      • 4.3.2.1 Phase II market, 2018 - 2030 (USD Million)
    • 4.3.3 Phase III
      • 4.3.3.1 Phase III market, 2018 - 2030 (USD Million)
    • 4.3.4 Phase IV
      • 4.3.4.1 Phase IV market, 2018 - 2030 (USD Million)

Chapter 5 Oncology Clinical Trials Market: Study Design Analysis

  • 5.1 Study Design Movement Analysis & Market Share, 2022 & 2030
  • 5.2 Oncology Clinical Trials Market Estimates & Forecast, By Study Design (USD Million)
  • 5.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the Study Design
    • 5.3.1 Interventional
      • 5.3.1.1 Interventional market, 2018 - 2030 (USD Million)
    • 5.3.2 Observational
      • 5.3.2.1 Observational market, 2018 - 2030 (USD Million)
    • 5.3.3 Expanded access trials
      • 5.3.3.1 Expanded Access market, 2018 - 2030 (USD Million)

Chapter 6 Oncology Clinical Trials Market: Regional Estimates & Trend Analysis

  • 6.1 Oncology Clinical Trials Market: Regional Outlook
  • 6.2 North America
    • 6.2.1 North america oncology clinical trials market estimates & Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 Key country dynamics
      • 6.2.2.2 U.S. oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Key country dynamics
      • 6.2.3.2 Canada oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3 Europe
      • 6.3.1.1 Europe oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 UK
      • 6.3.2.1 Key country dynamics
      • 6.3.2.2 UK oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Key country dynamics
      • 6.3.3.2 Germany oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4 France
      • 6.3.4.1 Key country dynamics
      • 6.3.4.2 France oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5 Italy
      • 6.3.5.1 Key country dynamics
      • 6.3.5.2 Italy oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.6 Spain
      • 6.3.6.1 Key country dynamics
      • 6.3.6.2 Spain oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.7 Sweden
      • 6.3.7.1 Key country dynamics
      • 6.3.7.2 Sweden oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.8 Denmark
      • 6.3.8.1 Key country dynamics
      • 6.3.8.2 Denmark oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.9 NORWAY
      • 6.3.9.1 Key country dynamics
      • 6.3.9.2 Norway oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4 ASIA Pacific
      • 6.4.1.1 Asia Pacific oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Key country dynamics
      • 6.4.2.2 Japan oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 Key country dynamics
      • 6.4.3.2 China oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 Key country dynamics
      • 6.4.4.2 India oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.5 Australia
      • 6.4.5.1 Key country dynamics
      • 6.4.5.2 Australia oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.6 South Korea
      • 6.4.6.1 Key country dynamics
      • 6.4.6.2 South Korea oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.7 Thailand
      • 6.4.7.1 Key country dynamics
      • 6.4.7.2 Thailand oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5 Latin America
      • 6.5.1.1 Latin America oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Key country dynamics
      • 6.5.2.2 Brazil oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Key country dynamics
      • 6.5.3.2 Mexico oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4 Argentina
      • 6.5.4.1 Key country dynamics
      • 6.5.4.2 Argentina oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6 Middle East & Africa
      • 6.6.1.1 Middle East & Africa oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 Key country dynamics
      • 6.6.2.2 South Africa oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3 Saudi Arabia
      • 6.6.3.1 Key country dynamics
      • 6.6.3.2 Saudi Arabia oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4 UAE
      • 6.6.4.1 Key country dynamics
      • 6.6.4.2 UAE oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5 Kuwait
      • 6.6.5.1 Key country dynamics
      • 6.6.5.2 Kuwait oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Company Competitive Landscape
  • 7.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2 Market Participant Categorization
    • 7.2.1 AstraZeneca
      • 7.2.1.1 Company overview
      • 7.2.1.2 Financial performance
      • 7.2.1.3 Phase benchmarking
      • 7.2.1.4 Strategic initiatives
    • 7.2.2 Merck & Co., Inc
      • 7.2.2.1 Company overview
      • 7.2.2.2 Financial performance
      • 7.2.2.3 Phase benchmarking
      • 7.2.2.4 Strategic initiatives
    • 7.2.3 IQVIA Inc
      • 7.2.3.1 Company overview
      • 7.2.3.2 Financial performance
      • 7.2.3.3 Phase benchmarking
      • 7.2.3.4 Strategic initiatives
    • 7.2.4 Gilead Sciences, Inc
      • 7.2.4.1 Company overview
      • 7.2.4.2 Financial performance
      • 7.2.4.3 Phase benchmarking
      • 7.2.4.4 Strategic initiatives
    • 7.2.5 F. Hoffmann-La Roche Ltd
      • 7.2.5.1 Company overview
      • 7.2.5.2 Financial performance
      • 7.2.5.3 Phase benchmarking
      • 7.2.5.4 Strategic initiatives
    • 7.2.6 PAREXEL International Corporation
      • 7.2.6.1 Company overview
      • 7.2.6.2 Financial performance
      • 7.2.6.3 Phase benchmarking
      • 7.2.6.4 Strategic initiatives
    • 7.2.7 PRA Health Sciences
      • 7.2.7.1 Company overview
      • 7.2.7.2 Financial performance
      • 7.2.7.3 Phase benchmarking
      • 7.2.7.4 Strategic initiatives
    • 7.2.8 Medpace
      • 7.2.8.1 Company overview
      • 7.2.8.2 Financial performance
      • 7.2.8.3 Phase benchmarking
      • 7.2.8.4 Strategic initiatives
    • 7.2.9 Pivotal
      • 7.2.9.1 Company overview
      • 7.2.9.2 Financial performance
      • 7.2.9.3 Phase benchmarking
      • 7.2.9.4 Strategic initiatives

Chapter 8 Analyst Perspective

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 3 North America oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 4 North America oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 5 U.S. oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 6 U.S. oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 7 Canada oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 8 Canada oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 9 Europe oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 10 Europe oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 11 Europe oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 12 Germany oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 13 Germany oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 14 UK oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 15 UK oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 16 France oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 17 France oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 18 Italy oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 19 Italy oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 20 Spain oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 21 Spain oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 22 Sweden oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 23 Sweden oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 24 Norway oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 25 Norway oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 26 Denmark oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 27 Denmark oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 28 Asia Pacific oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 29 Asia Pacific oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 30 Asia Pacific oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 31 China oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 32 China oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 33 Japan oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 34 Japan oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 35 India oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 36 India oncology clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 37 Australia oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 38 Australia oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 39 Thailand oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 40 Thailand oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 41 South Korea oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 42 South Korea oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 43 Latin America oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 44 Latin America oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 45 Latin America oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 46 Brazil oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 47 Brazil oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 48 Brazil oncology clinical trials market, by application, 2018 - 2030 (USD million)
  • Table 49 Mexico oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 50 Mexico oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 51 Argentina oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 52 Argentina oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 53 Middle East and Africa oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 54 Middle East and Africa oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 55 Middle East and Africa oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 56 South Africa oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 57 South Africa oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 58 Saudi Arabia oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 59 Saudi Arabia oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 60 UAE oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 61 UAE oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 62 Kuwait oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 63 Kuwait oncology clinical trials market, by study design, 2018 - 2030 (USD million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Oncology clinical trials: Market outlook
  • Fig. 9 Oncology clinical trials: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Oncology clinical trials market driver impact
  • Fig. 15 Oncology clinical trials market restraint impact
  • Fig. 16 Oncology clinical trials market strategic initiatives analysis
  • Fig. 17 Oncology clinical trials market: Type movement analysis
  • Fig. 18 Oncology clinical trials market: type outlook and key takeaways
  • Fig. 19 Phase I market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 20 Phase II market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 21 Phase III market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Phase IV market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Oncology clinical trials market: study design movement analysis
  • Fig. 25 Oncology clinical trials market: study design outlook and key takeaways
  • Fig. 26 Interventional studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 27 Observational studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 Expanded access studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 29 Global oncology clinical trials market: Regional movement analysis
  • Fig. 30 Global oncology clinical trials market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD million)